Your IGF-1 baseline before a GH peptide: what a high number actually means

You paid for an IGF-1 test before your first GHRH or GHRP peptide, the result came back as a single number, and now you are staring at it with no idea what it means for you. There is a real gap here. Labs report IGF-1 against an age and sex range, but almost nobody explains what a high, normal, or low baseline actually changes about starting a growth-hormone peptide. This is how to read that number honestly, and what it does and does not tell you.

What IGF-1 is, and why it falls with age

IGF-1 (insulin-like growth factor 1) is the downstream messenger of growth hormone. The pituitary releases GH in pulses, the liver responds by making IGF-1, and IGF-1 carries most of GH's tissue effects. Because it is more stable in the blood than GH's short pulses, a single IGF-1 draw is the standard proxy for how much GH signaling is going on.

It drops steeply with age. GH output falls sharply through the 30s, the same window as andropause and menopause, and IGF-1 tracks it down from 18 to 30 to 50. That decline, sometimes called somatopause, is the entire premise behind taking a secretagogue: you are trying to nudge an aging axis back toward a younger output. The evidence that these peptides raise GH and IGF-1 in humans is moderate. The evidence that the raise buys the downstream outcomes people actually want, body composition, recovery, longevity, is weak. Hold both of those in mind before you read too much into one value.

Why a "high" baseline changes the math

A lab flags your IGF-1 against an age-and-sex-adjusted reference range, so "high" means high for your age, not high on an absolute scale. If a young user already sits in the upper part of their range, two things follow.

First, the headroom is smaller. Secretagogues push IGF-1 up. Community protocols pairing tesamorelin with ipamorelin report driving it into the high 380s to 390s, described as "puberty levels" (anecdotal, and those numbers are not from a trial). Starting from an already-high baseline means you reach those elevated ranges faster, with less room before you are in genuinely supraphysiologic territory.

Second, the part no consumer guide says out loud: IGF-1 is a growth factor, and the longevity literature runs the other way. Lower lifetime IGF-1 signaling is associated with longer life across several models. Deliberately driving a young, already-high IGF-1 higher is pulling the growth lever hard, and the honest position is that the long-term risk-benefit of that is not settled. There is a countervailing argument, that GH is thymo-regenerative and so more GH could raise immune surveillance, but that is mechanistic speculation, not an outcome anyone has demonstrated. A high baseline is exactly the situation where "more" is least obviously better.

What the number cannot tell you

It cannot tell you the compound is safe for you, and it cannot tell you a dose. A baseline is a starting coordinate, not a green light. It also does not capture the two costs that matter most on these protocols.

• Insulin resistance. Raising GH and IGF-1 tends to worsen insulin sensitivity, and that cost is larger with tesamorelin, larger still when tesamorelin is stacked with ipamorelin. An IGF-1 number says nothing about your glucose handling. That needs its own markers.
• The prostate. In one documented self-report, sermorelin spiked a previously in-range PSA, which reverted after stopping. It is a single n-of-1, but PSA monitoring on any GH-axis protocol is prudent, and a baseline IGF-1 draw is a good moment for a man to also capture a baseline PSA.

What to pair with the baseline

If you are testing IGF-1 before starting, the useful move is to make it one point in a small panel rather than a lone number: IGF-1, a fasting glucose and insulin for the insulin-resistance cost, and for men a PSA. The one research-grade framing that exists, a proposed protocol of cyclical tesamorelin run under clinician guidance with IGF-1 targeted and thymic imaging plus CD4/CD8 counts before and after, is explicitly clinician-run and still speculative. That is the level of monitoring the people thinking hardest about this consider appropriate. It is a long way from "test once, read a forum, start."

Know the acute warning signs regardless of your baseline. Flushing, hot or itchy skin, or heart palpitations after a dose are allergic-reaction signals on GHRH and GHRP peptides, and the correct response is to stop, not to push through. The old "a bit of flushing means it is working" framing is wrong.

The honest gap

There is no validated consumer reference for what a "safe" pre-peptide IGF-1 is in a young, healthy person, because the outcome studies that would define one do not exist. What you have is an age-adjusted range, a moderate-evidence expectation that peptides will raise the number, weak evidence about what that raise does over years, and a real, unresolved tension between the growth signal you are buying and the longevity signal you may be spending. A high baseline does not automatically rule anything out, but it is the number that most argues for slowing down and involving a clinician, not for starting faster.

Before you source anything for a protocol like this, the same rules apply as everywhere else: how to vet a peptide seller, and what to actually measure before you can tell if a peptide worked. More on the peptide landscape on the blog.

FAQ

What is a normal IGF-1 level before starting a peptide?

Labs report IGF-1 against an age-and-sex-adjusted range, so "normal" is defined relative to your age, not a single universal number. A result inside the range is not a clearance to start a growth-hormone peptide, it is one data point to discuss with a clinician alongside glucose and, for men, PSA.

Does a high IGF-1 baseline mean I should not take a GH peptide?

Not automatically, but it is the baseline that most argues for caution. IGF-1 is a growth factor, secretagogues push it higher, and an already-high starting point reaches elevated levels faster with less headroom. The long-term risk-benefit of driving a young, high IGF-1 higher is not settled, so it is a clinician conversation, not a forum decision.

What should I test alongside IGF-1?

A useful baseline panel is IGF-1 plus fasting glucose and insulin (GH peptides tend to worsen insulin sensitivity, more so with tesamorelin), and for men a PSA (a documented self-report tied a PSA spike to sermorelin). One number in isolation misses the costs that matter most.

Are the "puberty level" IGF-1 targets people mention safe?

Those figures, community reports of high-380s to 390s on tesamorelin plus ipamorelin, are anecdotal and not trial-derived, and they describe supraphysiologic signaling in adults. There is moderate evidence peptides raise IGF-1 and weak evidence about what sustained elevation does over time. Treat "puberty levels" as a marketing frame, not a validated safety target.